Younger patients often require repeat corneal crosslinking, study finds

March 14th 2025

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Prophylactic cyclosporine A 0.1% eye drops were associated with improved ocular surface homeostasis and reduced inflammation

Wooden blocks which say PHASE and a block at the end with the numbers 1/2. The last block is switching from 1 to 2. This represents a clinical trial moving through phases. Image credit: ©rabbitti – stock.adobe.com

Study links new gender and genetic factors to Fuchs Endothelial Corneal Dystrophy

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

Figure. Slit-scanning in vivo confocal microscopy images of the corneal endothelium: A (left) demonstrates a healthy control cornea: Image of a normal corneal endothelium, showing a uniform hexagonal cell pattern with consistent cell density and no visible guttae or abnormalities (white solid arrowhead). B (right) shows FECD: Increased confluency of guttata, illustrating a more extensive presence of these structures. Images courtesy UCL/NIHR Moorfields Biomedical Research Centre.

Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care

A large-scale study indicates women are more likely to develop the inherited corneal condition

Left to Right – Back Row: Peter Holland, CEO, IAPB, H.E. Gladys Mokhawa, Permanent Representative of Botswana to the United Nations, H.E Ambassador Walton Webson, Permanent Representative of Antigua and Barbuda to the United Nations & Co-Chair and Founder of the UN Friends of Vision Group, Dr. A.H. Monjurul Kabir, Global Adviser and Team Leader, Gender Equality and Disability Inclusion, Mr. Werner Obermeyer, Director WHO, New York Front Row: Jennifer Gersbeck, Executive Director – Influence and Scaling Impact at The Fred Hollows Foundation and Co-Chair of the IAPB Gender Equity Work Group, HRH The Duchess of Edinburgh, Ms Tara Soomro, Permanent Mission of United Kingdom to the United Nations & Ambassador ECOSOC Affairs . Image courtesy of the International Agency for the Prevention of Blindness.

March 12th 2025

OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

A black-and-white image of a woman placing her hand over her eye, as if in pain. A red glow on her eye area indicates she is experiencing neuropathic corneal pain. Image credit: ©mykolasamoilenk – stock.adobe.com

Martin David Harp

March 11th 2025

Novel stem cell therapy restores corneal damage previously believed irreversible

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

An illustration of an eye's iris and pupil, suspended on a dark background which evokes the depth of outer space. Image credit: ©Enis – stock.adobe.com

March 4th 2025

Study assesses efficacy of cyclosporine A 0.1% cationic emulsion drops for postoperative discomfort

The authors said their results provide strong support that cultivated autologous limbal epithelial cell transplantation is safe and feasible

Related Content

March 14th 2025

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Prophylactic cyclosporine A 0.1% eye drops were associated with improved ocular surface homeostasis and reduced inflammation

Study links new gender and genetic factors to Fuchs Endothelial Corneal Dystrophy

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care

A large-scale study indicates women are more likely to develop the inherited corneal condition

March 12th 2025

OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

Martin David Harp

March 11th 2025

Novel stem cell therapy restores corneal damage previously believed irreversible

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

March 4th 2025